Exelixis Past Earnings Performance
Past criteria checks 4/6
Exelixis's earnings have been declining at an average annual rate of -11.4%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 21.1% per year. Exelixis's return on equity is 12.3%, and it has net margins of 18.8%.
Key information
-11.4%
Earnings growth rate
-12.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 21.1% |
| Return on equity | 12.3% |
| Net Margin | 18.8% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Exelixis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 1,638 | 308 | 440 | 777 |
| 30 Jun 22 | 1,555 | 273 | 426 | 742 |
| 31 Mar 22 | 1,521 | 298 | 402 | 691 |
| 31 Dec 21 | 1,435 | 231 | 402 | 694 |
| 30 Sep 21 | 1,254 | 164 | 385 | 626 |
| 30 Jun 21 | 1,157 | 94 | 371 | 639 |
| 31 Mar 21 | 1,031 | 65 | 333 | 605 |
| 31 Dec 20 | 988 | 112 | 293 | 548 |
| 30 Sep 20 | 958 | 152 | 269 | 488 |
| 30 Jun 20 | 998 | 282 | 232 | 409 |
| 31 Mar 20 | 979 | 294 | 231 | 376 |
| 31 Dec 19 | 968 | 321 | 228 | 337 |
| 30 Sep 19 | 956 | 612 | 223 | 300 |
| 30 Jun 19 | 910 | 642 | 219 | 247 |
| 31 Mar 19 | 856 | 650 | 212 | 208 |
| 31 Dec 18 | 854 | 690 | 206 | 182 |
| 30 Sep 18 | 745 | 368 | 200 | 157 |
| 30 Jun 18 | 672 | 323 | 190 | 141 |
| 31 Mar 18 | 585 | 253 | 179 | 127 |
| 31 Dec 17 | 452 | 154 | 159 | 112 |
| 30 Sep 17 | 410 | 150 | 126 | 104 |
| 30 Jun 17 | 320 | 58 | 120 | 95 |
| 31 Mar 17 | 257 | 6 | 116 | 90 |
| 31 Dec 16 | 191 | -70 | 116 | 96 |
| 30 Sep 16 | 124 | -147 | 120 | 96 |
| 30 Jun 16 | 71 | -181 | 106 | 101 |
| 31 Mar 16 | 43 | -186 | 83 | 103 |
| 31 Dec 15 | 37 | -162 | 57 | 96 |
Quality Earnings: EX9 has high quality earnings.
Growing Profit Margin: EX9's current net profit margins (18.8%) are higher than last year (13.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EX9's earnings have declined by 11.4% per year over the past 5 years.
Accelerating Growth: EX9's earnings growth over the past year (87.2%) exceeds its 5-year average (-11.4% per year).
Earnings vs Industry: EX9 earnings growth over the past year (87.2%) exceeded the Biotechs industry -26.8%.
Return on Equity
High ROE: EX9's Return on Equity (12.3%) is considered low.